Broker calls go mixed as Motilal stays bullish on UTI AMC while Goldman cuts Dr Reddy’s

Published on 25 April 2026

Goldman warns weak pipeline visibility and pricing pressure

Brokerages are taking a selective approach in markets: Motilal Oswal has maintained a buy view on UTI AMC, citing steady AUM growth and healthy SIP inflows, as well as a bullish stance on Aditya Birla Sun Life AMC. In contrast, Goldman Sachs downgraded Dr Reddy’s Laboratories, pointing to weak pipeline visibility, pricing pressure, and limited near-term growth.

Motilal Oswal stays bullish on UTI AMC on steady AUM and SIP inflows
Aditya Birla Sun Life AMC also sees a positive stance from Motilal Oswal
Goldman Sachs downgrades Dr Reddy’s on weak pipeline visibility
Pricing pressure and limited near-term opportunities drive the cut

#mutual funds #equity markets #stock picks #brokerages #pharma

Read the full story at The Economic Times

This summarization was done by Beige for a story published on The Economic Times

Broker calls go mixed as Motilal stays bullish on UTI AMC while Goldman cuts Dr Reddy’s

The full experience is on mobile.